Nanoparticulation of Prodrug into Medicines for Cancer Therapy

dc.contributor.authorZhang Yuezhou
dc.contributor.authorCui Huaguang
dc.contributor.authorZhang Ruiqi
dc.contributor.authorZhang Hongbo
dc.contributor.authorHuang Wei
dc.contributor.organizationfi=Turun biotiedekeskus|en=Turku Bioscience Centre|
dc.contributor.organization-code1.2.246.10.2458963.20.18586209670
dc.converis.publication-id66860641
dc.converis.urlhttps://research.utu.fi/converis/portal/Publication/66860641
dc.date.accessioned2022-10-28T13:22:14Z
dc.date.available2022-10-28T13:22:14Z
dc.description.abstractThis article provides a broad spectrum about the nanoprodrug fabrication advances co-driven by prodrug and nanotechnology development to potentiate cancer treatment. The nanoprodrug inherits the features of both prodrug concept and nanomedicine know-how, attempts to solve underexploited challenge in cancer treatment cooperatively. Prodrugs can release bioactive drugs on-demand at specific sites to reduce systemic toxicity, this is done by using the special properties of the tumor microenvironment, such as pH value, glutathione concentration, and specific overexpressed enzymes; or by using exogenous stimulation, such as light, heat, and ultrasound. The nanotechnology, manipulating the matter within nanoscale, has high relevance to certain biological conditions, and has been widely utilized in cancer therapy. Together, the marriage of prodrug strategy which shield the side effects of parent drug and nanotechnology with pinpoint delivery capability has conceived highly camouflaged Trojan horse to maneuver cancerous threats.
dc.identifier.eissn2198-3844
dc.identifier.jour-issn2198-3844
dc.identifier.olddbid181595
dc.identifier.oldhandle10024/164689
dc.identifier.urihttps://www.utupub.fi/handle/11111/38610
dc.identifier.urnURN:NBN:fi-fe2021093048450
dc.language.isoen
dc.okm.affiliatedauthorZhang, Hongbo
dc.okm.discipline1182 Biochemistry, cell and molecular biologyen_GB
dc.okm.discipline1182 Biokemia, solu- ja molekyylibiologiafi_FI
dc.okm.internationalcopublicationinternational co-publication
dc.okm.internationalityInternational publication
dc.okm.typeA2 Scientific Article
dc.publisherWILEY
dc.publisher.countryGermanyen_GB
dc.publisher.countrySaksafi_FI
dc.publisher.country-codeDE
dc.relation.articlenumber2101454
dc.relation.doi10.1002/advs.202101454
dc.relation.ispartofjournalAdvanced Science
dc.relation.issue18
dc.relation.volume8
dc.source.identifierhttps://www.utupub.fi/handle/10024/164689
dc.titleNanoparticulation of Prodrug into Medicines for Cancer Therapy
dc.year.issued2021

Tiedostot

Näytetään 1 - 1 / 1
Ladataan...
Name:
advs.202101454.pdf
Size:
11.91 MB
Format:
Adobe Portable Document Format
Description:
Publisher's pdf